NASDAQ · PSNL
Healthcare · Medical - Diagnostics & Research
$16.03
Down-$0.37 (-2.26%)
Updated Oct 7, 2026, 5:53 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PSNL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PSNL closed at $16.03 after 21 trading sessions, down 3.43% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $16.25 | $16.58 | $15.84 | $16.03 | 5.66M |
| Oct 5, 2026 | $16.12 | $16.47 | $16.02 | $16.40 | 1.7M |
| Oct 2, 2026 | $16.38 | $16.44 | $16.12 | $16.28 | 1.14M |
| Oct 1, 2026 | $16.22 | $16.315 | $16.07 | $16.17 | 1.66M |
| Sep 30, 2026 | $16.42 | $16.59 | $16.26 | $16.28 | 984.13K |
| Sep 29, 2026 | $16.25 | $16.47 | $16.08 | $16.35 | 1.04M |
| Sep 28, 2026 | $16.22 | $16.48 | $16.00 | $16.32 | 1.67M |
| Sep 25, 2026 | $16.74 | $16.77 | $16.38 | $16.46 | 1.02M |
| Sep 24, 2026 | $16.16 | $16.63 | $16.10 | $16.57 | 1.71M |
| Sep 23, 2026 | $16.16 | $16.42 | $16.09 | $16.35 | 1.12M |
| Sep 22, 2026 | $16.29 | $16.48 | $16.13 | $16.36 | 1.37M |
| Sep 21, 2026 | $16.38 | $16.50 | $16.07 | $16.24 | 1.82M |
| Sep 18, 2026 | $16.30 | $16.44 | $16.1202 | $16.40 | 3.18M |
| Sep 17, 2026 | $16.42 | $16.45 | $16.13 | $16.23 | 5.65M |
| Sep 16, 2026 | $16.20 | $16.39 | $15.96 | $16.11 | 2.26M |
| Sep 15, 2026 | $16.15 | $16.40 | $15.915 | $16.10 | 2.43M |
| Sep 14, 2026 | $16.15 | $16.40 | $16.05 | $16.29 | 1.69M |
| Sep 11, 2026 | $16.46 | $16.58 | $16.19 | $16.21 | 1.41M |
| Sep 10, 2026 | $16.07 | $16.49 | $16.00 | $16.33 | 2.3M |
| Sep 9, 2026 | $16.60 | $16.825 | $16.38 | $16.40 | 2.78M |
| Sep 8, 2026 | $17.20 | $17.35 | $16.46 | $16.60 | 2.55M |
The latest Smart Investors Daily articles mentioning PSNL.
Company
Market Activity
Research & News
PSNL research
Company profile and research snapshot.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | BTIG | Neutral | — |
| Jul 20, 2026 | Needham | Hold | — |
| Jul 20, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | Lake Street | Hold | — |
| Jul 17, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 22, 2026
Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business. Speaking at Morgan Stanley’s Global Healthcare Conference, Lefkofsky said the diagnost
Yahoo · Sep 17, 2026
Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the last five sessions. in which Tempus is the third-largest position behind Tesla and SpaceX rose 4.3%.
Yahoo · Sep 1, 2026
Personalis holders receive Tempus shares worth $16.25 each under the pending merger
Yahoo · Sep 1, 2026
Tempus AI (NASDAQ:TEM) shares rose 2. 7% in pre-market trading following analyst actions from Piper Sandler and Canaccord Genuity as investors assessed the company’s pending acquisition of Personalis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PSNL.
